SCHEMBL2900756

SCHEMBL2900756

[CH]=Cc1cc2ccccc2o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.64
APP P05067 1/20 0.47
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
MAPK1 P28482 2/20 0.45
MAPT P10636 1/20 0.45
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
FLT3 P36888 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.44
MGLL Q99685 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PIM1 P11309 1/20 0.43
TYR P14679 1/20 0.42
DAO P14920 1/20 0.42
AKR1B1 P15121 1/20 0.42
HPGD P15428 1/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA2 P00918 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9026552 0.78 CYP2A6 (0.64) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL29502957 0.78 CYP2A6 (1.00) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL17185672 0.78 CYP2A6 (0.64) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL225144 0.78 CYP2A6 (0.64) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL1706926 0.78 CYP2A6 (0.64) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL91009 0.78 CYP2A6 (1.00) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL11396362 0.78 CYP2A6 (0.64) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL9956377 0.78 CYP2A6 (1.00) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL946001 0.78 CYP2A6 (0.58) CYP2A6APPRAB9ANPC1MAPK1
SCHEMBL1176914 0.75 CYP2A6 (0.60) CYP2A6APPRAB9ANPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2759543-B1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORP (JP) 2017-07-19 EP disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
EP-2725017-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2016-06-29 EP disclosed
EP-2669277-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-07-01 EP disclosed
EP-2684886-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-06-03 EP disclosed
EP-2669278-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-05-27 EP disclosed
US-8916071-B2 Chromene compound and curable composition TOKUYAMA CORPORATION (JP) 2014-12-23 US disclosed
EP-2554624-B1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORP (JP) 2014-11-05 EP disclosed
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2014-08-14 US disclosed
EP-2759543-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION Tokuyama Corporation (JP) 2014-07-30 EP disclosed
US-20040237837-A1 Lightfast additive having UV-absorbing moiety and ink composition including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2004-12-02 US disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
US-6469076-B1 Chromene compounds TOKUYAMA CORPORATION (JP) 2002-10-22 US disclosed
EP-1054010-B1 Chromene compound TOKUYAMA CORP (JP) 2002-07-24 EP disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
US-6340765-B1 PHOTOCHROMIC DYES AND DEVELOPMENT TOKUYAMA CORPORATION (JP) 2002-01-22 US disclosed
EP-1116723-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-07-18 EP disclosed
EP-1054010-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040237837-A1 Lightfast additive having UV-absorbing moiety and ink composition including the same CDK4, CDKL4, UGT1A4 CYP2A6 1337/4885APP 3547/4885RAB9A 3228/4885
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 CYP2A6 2241/4885APP 3013/4885RAB9A 2560/4885
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION CRY2, CRY1, CDYL CYP2A6 798/4885APP 3110/4885RAB9A 3560/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 CYP2A6 2342/4885APP 2680/4885RAB9A 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.